Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B.
Various formulations have been developed in an effort to reduce the toxicity of amphotericin B. We report a case of cryptococcal meningitis in a 31-year-old HIV-positive man which was successfully treated with amphotericin B lipid emulsion.
Leake
H A
HA
Department of Medicine, Brighton Health Care, U.K.
Appleyard
M N
MN
Hartley
J P
JP
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects*; D004352:Drug Resistance, Microbial; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage*; D005437:Flucytosine / Q000627:therapeutic use; D006679:HIV Seropositivity; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced*; D008297:Male; D016919:Meningitis, Cryptococcal / Q000188:drug therapy*
D005217:Fat Emulsions, Intravenous; D017964:Itraconazole; D000666:Amphotericin B; D005437:Flucytosine